China approves use of Pfizer's Covid drug Paxlovid
Add BT as a preferred source
[BEIJING] China's medical products regulator said on Saturday (Feb 12) it has given conditional approval for Pfizer's Covid-19 treatment Paxlovid, making it the first oral anti-coronavirus pill approved in the country to treat the disease.
The National Medical Products Administration said Paxlovid has obtained conditional approval to treat adults who have mild to moderate Covid-19 and high risk of progressing to a severe condition. Further study on the drug needed to be conducted and submitted to the authority, it said.
It is not immediately clear if China is already in talks with Pfizer to procure the pill. Pfizer did not reply to a Reuters request for comment. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Orchard plot, Jurong East EC, Raffles Town Club site among 10 new housing parcels in H2 GLS plan
Geopolitical risks must be considered before investing in tech: Temasek chairman Teo Chee Hean
Don’t just pump money – Temasek’s portfolio firms, markets must create inherent value: Teo Chee Hean
Indonesia’s commodity export shake-up sparks industry alarm, investor jitters
